Squarepoint
TLOG

Squarepoint’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Squarepoint’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,100
Closed -$2K – 1502
2016
Q1 		$2K Buy
+11,100
New +$3.08K ﹤0.01% 1113

Other funds holding TLOG

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Squarepoint's TLOG Position: Q2 2016 in Review

Squarepoint sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2016, closing a stake of 11,100 shares — an estimated $2K sold.

Squarepoint first reported a position in TLOG in Q1 2016 and held it in 1 quarter. The position peaked at $2K in Q1 2016. 19 funds tracked by Wall St. Rank hold TLOG as of Q2 2016.

  • Squarepoint reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2016 after selling out during the quarter.
  • Squarepoint sold 11,100 TetraLogic Pharmaceuticals Corporation shares in Q2 2016, an estimated $2K.
  • Squarepoint first reported a position in TetraLogic Pharmaceuticals Corporation in Q1 2016 and held it in 1 quarter.
  • Squarepoint's TetraLogic Pharmaceuticals Corporation position peaked at $2K in Q1 2016.
  • 19 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2016.

Based on Squarepoint's 13F filing for Q2 2016, filed 15 Aug 2016.